

**Supplementary Table 2.** Clinical characteristics of patients with type 2 diabetes mellitus according to INSA positivity

Characteristic	INSA (+) (n=12)	INSA (-) (n=88)	P value
<b>At diagnosis</b>			
Age, yr	12.50 (10.00–15.50)	14.00 (12.00–15.00)	0.447
Female sex	6 (50.0)	33 (37.5)	0.530
BMI z-score	2.54±1.89	2.13±1.65	0.429
Acanthosis nigricans	5 (41.7)	36 (40.9)	1.000
SGA	0	9 (10.3)	0.595
Family history	12 (100.0)	68 (77.3)	0.117
Glucose, mg/dL	234.0 (139.0–293.0)	252.0 (159.5–352.5)	0.362
HbA1c, %	9.10 (7.70–11.30)	10.70 (8.20–12.55)	0.183
Insulin, µIU/mL	22.7 (14.9–68.3)	13.9 (8.8–36.7)	0.155
Serum C-peptide, ng/mL	4.90 (3.60–8.40)	3.20 (1.80–4.90)	0.070
Urine C-peptide, µg/day	8.48 (4.30–95.25)	15.40 (5.38–34.56)	0.862
TGAb or TPOAb	0	3 (3.4)	1.000
DKA	2 (16.7)	13 (14.8)	1.000
Treatment			0.969
Metformin only	4 (33.3)	24 (27.3)	
Insulin only	4 (33.3)	23 (26.1)	
Metformin+Insulin	4 (33.3)	35 (39.8)	
No medication	0	6 (6.8)	
<b>At the last follow-up</b>			
Age, yr	14.50 (11.50–17.50)	15.00 (13.50–17.00)	0.665
Follow up duration, yr	1.38 (0.79–2.67)	1.08 (0.42–1.92)	0.405
BMI z-score	2.30±1.93	2.17±1.64	0.798
HbA1c, %	6.20 (5.50–6.80)	6.10 (5.55–7.10)	0.933
TGAb or TPOAb	0	3 (3.4)	1.000
Treatment			0.287
Metformin only	5 (41.7)	44 (50.0)	
Insulin only	1 (8.3)	4 (4.5)	
Metformin+Insulin	5 (41.7)	26 (29.5)	
No medication	1 (8.3)	14 (15.9)	

Values are presented as median (range), number (%), or mean ± standard deviation.

INSA, insulin autoantibody; BMI, body mass index; SGA, small for gestational age; HbA1c, glycosylated hemoglobin; TGAb, thyroglobulin antibody; TPOAb, thyroid peroxidase antibody; DKA, diabetic ketoacidosis.